Bacteria-mediated immunotheraphy
Employees: 11-50
Total raised: $5M
Founded date: 2018
Investors 2
| Date | Name | Website |
| - | Muirwoods ... | muirwoodsv... |
| 23.08.2025 | Yuanta Inv... | yuantainve... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 25.07.2019 | Seed | $5M | - |
Mentions in press and media 8
| Date | Title | Description |
| 13.11.2025 | LISCure Expands Global Partnerships for BBB Shuttle Platform 'ExoPN-101'; Signs Fourth MTA with Leading Pharma Partner | SEOUL, South Korea, Nov. 13, 2025 /PRNewswire/ -- LISCure Biosciences ("LISCure"), a biotechnology company advancing next-generation therapeutics, today announced that it has entered into a new Material Transfer Agreement (MTA) wi... |
| 10.11.2025 | LISCure Biosciences Initiates Global Phase 2 Trial of LB-P8 in Primary Sclerosing Cholangitis (PSC) | SEOUL, South Korea, Nov. 10, 2025 /PRNewswire/ -- LISCure Biosciences ("LISCure"), a clinical-stage biopharmaceutical company, announced the initiation of patient dosing in a global Phase 2 clinical trial of LB-P8, a novel therape... |
| 29.03.2024 | LISCure Biosciences receives U.S. FDA Fast Track designation for LB-P8 for the treatment of primary sclerosing cholangitis (PSC) | Phase 2 study is underway and LB-P8 is the only live biotherapeutic product currently reported to be in clinical development for the treatment of PSC FDA's Fast Track designation for LB-P8 underlines the urgent need for treatment options to... |
| 08.12.2022 | LISCure's Phase 2 Drug Candidate Granted Orphan Drug Designation (ODD) from US FDA | First Orphan Drug Designation (ODD) in the field of microbiome-based treatment for metabolic diseases SEOUL, South Korea, Dec. 8, 2022 /PRNewswire/ -- LB-P8, a novel drug being developed by LISCure Biosciences, Inc. (LISCure) as a treatment... |
| 28.10.2022 | LISCure Biosciences Announces Oral Presentation of New Drug Candidate for NASH at Upcoming AASLD The Liver Meeting 2022 | The efficacy and mechanism of NASH microbiome-based therapy for liver fibrosis, steatosis, and inflammation have been confirmed in various animal models SEOUL, South Korea, Oct. 28, 2022 /PRNewswire/ -- LISCure Biosciences, a clinical-stage... |
| 27.02.2021 | LISCure Biosciences Raises $21 million in Series B Funding | South Korea: On February 25th, 2021, LISCure Biosciences Inc., a biotech company that focuses on developing bacteria-mediated immunotherapy, announced that it has successfully completed $21 million of a Series B funding round. Participants ... |
| 26.02.2021 | South Korea-based biotech startup LISCure Biosciences secures $21M in funding to develop immunotherapy drugs to help the body immune system fight cancer | The use of immunotherapy treatments for cancer has been gaining momentum in recent years as government researchers and drug makers work together to find a lasting cure for cancer and other diseases. Unlike traditional drugs, immunotherapy i... |
| 25.07.2019 | Liscure Biosciences Raises $5M in Seed Funding | LISCure Biosciences, a Seoul, South Korea-based biotech company that researches and develops bacteria-mediated immunotherapy, raised $5m in seed funding. Backers included NHN Investment, Shinhan Investment, and KB Securities. The company in... |